KRAS and neoplasm: For patients with wild-type KRAS exon 2 tumours, median (95% CI) OS was 10.0 (8.7–11.4) months in the panitumumab plus BSC arm vs 7.4 (5.8–9.3) months in the BSC alone arm (HR=0.73; 95% CI=0.57–0.93; P=0.0096; Figure 2A, Table 2).